Literature DB >> 25810732

Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model.

Doo Sun Sim1, Myung Ho Jeong1, Dae Sung Park1, Jung Ha Kim1, Kyung Seob Lim1, Hyun Kuk Kim1, Sung Soo Kim1, Jae Yeong Cho1, Hae Chang Jeong1, Keun Ho Park1, Young Joon Hong1, Ju Han Kim1, Youngkeun Ahn1, Jeong Gwan Cho1, Jong Chun Park1.   

Abstract

BACKGROUND AND OBJECTIVES: We sought to evaluate the effect of the early use of ezetimibe/simvastatin (Vytorin®) on arterial healing and endothelialization after the implantation of a drug-eluting stent (DES) in a porcine model of coronary restenosis.
MATERIALS AND METHODS: A total of 20 pigs (40 coronary arteries) were randomly allocated to a pretreatment or no treatment group. The pretreatment group (n=20) received oral ezetimibe/simvastatin (10/20 mg) daily for 7 days before stenting and the no pretreatment group (n=20) did not. All pigs were treated with ezetimibe/simvastatin (10/20 mg) daily after stenting for 4 weeks. Stenting was performed using a bare-metal stent (BMS, n=10) and three types of DES: biolimus A9-eluting stent (BES, n=10), zotarolimus-eluting stent (ZES, n=10), and everolimus-eluting stents (EES, n=10). Four weeks later, pigs underwent a follow-up coronary angiography and were sacrificed for histopathologic analysis.
RESULTS: There were no significant differences between the pretreatment and no pretreatment groups in the internal elastic lamina area, lumen area, neointima area, stenotic area, injury score, fibrin score, and inflammation score. In both groups, the fibrin score was higher in pigs with DES than in BMS, particularly in ZES and EES. The inflammatory score was not different between DES and BMS.
CONCLUSION: In a porcine model of coronary restenosis, pretreatment with ezetimibe/simvastatin before DES implantation failed to improve arterial healing and endothelialization compared to treatment after stenting.

Entities:  

Keywords:  Coronary restenosis; Drug-eluting stents; Ezetimibe; Hydroxymethylglutaryl-CoA reductase inhibitors

Year:  2015        PMID: 25810732      PMCID: PMC4372976          DOI: 10.4070/kcj.2015.45.2.110

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


  30 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.

Authors:  Jung Sun Cho; Myung Ho Jeong; Doo Sun Sim; Young Joon Hong; Kyung Seob Lim; Jung Ha Kim; Hyoung Doo Kim; Ju Yeal Baek; Hee Jeoung Yoon; Sung-Ho Her; Seung Won Jin; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

3.  Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice.

Authors:  H R Davis; D S Compton; L Hoos; G Tetzloff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

4.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.

Authors:  J Dupuis; J C Tardif; P Cernacek; P Théroux
Journal:  Circulation       Date:  1999-06-29       Impact factor: 29.690

5.  Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.

Authors:  M van Heek; C Farley; D S Compton; L Hoos; H R Davis
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

Authors:  Boris Kerzner; John Corbelli; Stephan Sharp; Leslie J Lipka; Lorenzo Melani; Alexandre LeBeaut; Ramachandran Suresh; Pabak Mukhopadhyay; Enrico P Veltri
Journal:  Am J Cardiol       Date:  2003-02-15       Impact factor: 2.778

7.  Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis.

Authors:  Kristof Graf; Thore Dietrich; Michael Tachezy; Frank-Detlef Scholle; Kai Licha; Philipp Stawowy; Michael Grafe; Peter Hauff; Eckart Fleck
Journal:  Mol Imaging       Date:  2008 Mar-Apr       Impact factor: 4.488

8.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

Authors:  L Lacoste; J Y Lam; J Hung; G Letchacovski; C B Solymoss; D Waters
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

9.  Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model.

Authors:  Young Joon Hong; Myung Ho Jeong; Sang Rok Lee; Seo Na Hong; Kye Hun Kim; Hyung Wook Park; Ju Han Kim; Weon Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

10.  Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.

Authors:  Kyung Seob Lim; Myung Ho Jeong; In Ho Bae; Dae Sung Park; Jong Min Kim; Jung Ha Kim; Dong Lyun Cho; Doo Sun Sim; Keun-Ho Park; Young Joon Hong; Youngkeun Ahn
Journal:  Korean Circ J       Date:  2013-11-30       Impact factor: 3.243

View more
  1 in total

1.  Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heart disease between diabetic and non-diabetic patients.

Authors:  Liming Lin; Cheng Jin; Xiaoming Wei; Huiying Li; Jihong Shi; Shouling Wu; Xiaojie Yang; Xiangqian Qi
Journal:  Int J Clin Exp Med       Date:  2015-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.